Quick Answer
Praxis Precision Medicines, Inc. reported Total Revenue of $0.00 for fiscal year 2025.
Praxis Precision Medicines, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $0.00 -100.0% |
$8.55M +249.5% |
$2.45M | $0.00 | — | — |
| Net Income | -$303.27M -65.9% |
-$182.82M -48.3% |
-$123.28M +42.4% |
-$214.03M -28.1% |
-$167.06M -170.2% |
-$61.82M -74.1% |
| Diluted EPS | -$13.48 -32.0% |
-$10.21 +45.4% |
-$18.69 +73.2% |
-$69.65 -1667.8% |
-$3.94 +49.9% |
-$7.86 |
| Total Assets | $937.91M +94.1% |
$483.11M +449.3% |
$87.95M -23.6% |
$115.13M -60.7% |
$292.75M -3.4% |
$303.18M +535.7% |
| Cash and Equivalents | $357.33M +65.9% |
$215.37M +164.9% |
$81.30M +31.9% |
$61.62M -55.6% |
$138.70M -53.2% |
$296.61M +561.8% |
| Stockholders Equity | $878.14M +282.3% |
$229.68M +256.3% |
$64.47M -66.3% |
$191.02M -35.4% |
$295.92M | — |
| R&D Expense | $267.12M +75.3% |
$152.41M +75.7% |
$86.77M -44.0% |
$155.04M +28.9% |
$120.26M +167.4% |
$44.98M +52.2% |
| Operating Income | -$326.20M -63.0% |
-$200.16M -58.4% |
-$126.37M +41.2% |
-$214.99M -28.5% |
-$167.33M -170.0% |
-$61.97M -73.1% |
| Shares Outstanding | 25.20M +29.7% |
19.42M +120.9% |
8.79M +167.1% |
3.29M -92.7% |
45.30M +18.4% |
38.27M +2259.5% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $0.00 | -100.0% | — |
| Net Income | September 30, 2025 | -$73.93M | -42.4% | -3.9% |
| Diluted EPS | September 30, 2025 | -$3.36 | -22.2% | -1.5% |
| Total Assets | September 30, 2025 | $396.39M | -4.8% | -12.5% |
| Cash and Equivalents | September 30, 2025 | $149.53M | -11.3% | -5.0% |
| Stockholders Equity | September 30, 2025 | $343.50M | -10.2% | -15.0% |
| R&D Expense | September 30, 2025 | $65.80M | +57.1% | +4.4% |
| Operating Income | September 30, 2025 | -$78.36M | -37.9% | -3.0% |
| Shares Outstanding | September 30, 2025 | 21.17M | +19.0% | +0.6% |
- Praxis Precision Medicines, Inc. reported Total Revenue of $0.00 for fiscal year 2025.
- Praxis Precision Medicines, Inc. showed a decrease of -100.0% in Total Revenue compared to the prior fiscal year.
- Praxis Precision Medicines, Inc. reported Net Income of -$303.27 million for fiscal year 2025.
- Praxis Precision Medicines, Inc. showed a decrease of -65.9% in Net Income compared to the prior fiscal year.
- Praxis Precision Medicines, Inc. reported Diluted EPS of $13.48 per share (loss) for fiscal year 2025.
- Praxis Precision Medicines, Inc. showed a decrease of -32.0% in Diluted EPS compared to the prior fiscal year.
- Praxis Precision Medicines, Inc. reported Total Assets of $937.91 million for fiscal year 2025.
- Praxis Precision Medicines, Inc. showed an increase of +94.1% in Total Assets compared to the prior fiscal year.
- Praxis Precision Medicines, Inc. reported Cash and Equivalents of $357.33 million for fiscal year 2025.
- Praxis Precision Medicines, Inc. showed an increase of +65.9% in Cash and Equivalents compared to the prior fiscal year.
- Praxis Precision Medicines, Inc. reported Stockholders Equity of $878.14 million for fiscal year 2025.
- Praxis Precision Medicines, Inc. showed an increase of +97.1% in Stockholders Equity compared to the prior fiscal year.
- Praxis Precision Medicines, Inc. reported R&D Expense of $267.12 million for fiscal year 2025.
- Praxis Precision Medicines, Inc. showed an increase of +75.3% in R&D Expense compared to the prior fiscal year.
- Praxis Precision Medicines, Inc. reported Operating Income of -$326.20 million for fiscal year 2025.
- Praxis Precision Medicines, Inc. showed a decrease of -63.0% in Operating Income compared to the prior fiscal year.
- Praxis Precision Medicines, Inc. reported Shares Outstanding of 25.20 million shares for fiscal year 2025.
- Praxis Precision Medicines, Inc. showed an increase of +29.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: